Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06992271 · ClinicalTrials.gov registry record · NA

Comparing Two Eccentric Protocols on Muscle Damage

A NA study of Muscle Damage and Eccentric Hypertrophy, sponsored by New York Institute of Technology.

Recruiting
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT06992271 is a NA study of Muscle Damage and Eccentric Hypertrophy that is actively recruiting participants, run by New York Institute of Technology. The registered enrollment target is 16 participants, below the 42-participant average among 6 other Muscle Damage trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06992271, a NA study of Muscle Damage and Eccentric Hypertrophy, is actively recruiting participants, sponsored by New York Institute of Technology.

RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study will be to test whether a new way of weight training is more effective than typical weight training. The investigators expect that this new way will cause more exercise-induced muscle damage, which helps people build bigger muscles. Another purpose of this study will be to explore perceptions of how muscle soreness impacts participant activities of daily living.

Interventions

  • BEHAVIORAL Fast Eccentric
  • BEHAVIORAL Slow Eccentric

Study Locations (1)

New York

  • NYIT - Old Westbury

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2023-03-08
Est. Completion 2025-06-01
Phase NA

Sponsor

New York Institute of Technology

49 total trials

What the Registry Record Tells You About NCT06992271

The ClinicalTrials.gov registry entry for NCT06992271 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 6 other Muscle Damage trials with a reported enrollment target (62% lower). The listed sponsor is New York Institute of Technology, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Muscle Damage appearing as the primary indexed condition, and to 2 interventions - of which Fast Eccentric is the first listed.

NCT06992271 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06992271 about?

NCT06992271 is a clinical study titled "Comparing Two Eccentric Protocols on Muscle Damage". The purpose of this study will be to test whether a new way of weight training is more effective than typical weight training. The investigators expect that this new way will cause more exercise-induced muscle damage, which helps people build bigger muscles. Another purpose of this study will be to ...

What is the current status of trial NCT06992271?

This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2023-03-08. Estimated completion is 2025-06-01.

What conditions does trial NCT06992271 study?

This clinical trial studies the following conditions: Muscle Damage, Eccentric Hypertrophy.

What interventions are being tested in trial NCT06992271?

The interventions under investigation include: Fast Eccentric (BEHAVIORAL), Slow Eccentric (BEHAVIORAL).

Who is sponsoring clinical trial NCT06992271?

This trial is sponsored by New York Institute of Technology, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06992271 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscle Damage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.